September 20, 2020

The Niche

Knoepfler lab stem cell blog

COVID-19

3 min read

When you sit down to read science on the weekends lately, assuming you are not primarily a COVID-19 researcher, how much COVID stuff seeps into your reading? As I was going over some of this year’s recommended weekly reads posts here on The Niche, I’ve realized that an increasing amount of COVID-19 research has joined the list. Part of this is because of the explosion of cell therapy work and news on COVID, but also I’m just interested in the science of COVID. Before …Read More

10 min read

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with COVID-19. The reality is that that’s probably not going to happen. Even so, a whole range of people and firms are somewhat exaggerating and in a few cases outright …Read More

3 min read

There is always plenty of complicated, mixed-bag news on the stem cell and regenerative medicine front so it’s great to highlight when there’s some good news out there. Today’s post includes several such upbeat items. At the bottom I’ve included a list of some recent interesting publications as well. Good news on vision front: jCyte Therapy Deal with Santen Pharmaceutical. David Jensen over at California Stem Cell Report reported on this blockbuster deal for a quarter of a billion dollars. Jensen wrote: “The California …Read More

3 min read

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a long shot, but some investigational products seem relatively speaking more promising than others. Here are some of the main developments as of April 13, 2020. I will likely update …Read More